XOMA Royalty

XOMA · NASDAQ

Price unavailable right now.

No price history for this range.

About XOMA

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Employees
14
Headquarters
Emeryville, California
Listed
Jun 6, 1986
Sector
Health Care
Industry
Biotechnology
Website
xoma.com

Leadership

XOMA Royalty executives
NameTitleSince
Jack Wyszomierski——
Owen Hughes—2023
Thomas Burns——
Bradley Sitko——
Heather Franklin——
Natasha Hernday——
Barbara Kosacz——
Joseph Limber——
Matthew Perry——

Revenue by product and region

Fiscal year ended Dec 31, 2022: $6.03M total revenue

By region

  • United States$4.48M74.3%
  • Asia Pacific$1.55M25.7%

Similar companies

Companies in the same industry as XOMA Royalty

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.